Serum NGAL level

PreclinicalBiologic

YYonsei University

Serum NGAL level is one of 23 biologic programs targeting Cardiac Arrest. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiac ArrestActive, not recruiting

Cardiac ArrestPreclinical

Active, not recruiting

Competition

Competitive Landscape

27 competitors in Cardiac Arrest

#DrugCompanyPhaseTrials

Brilinta

AstraZeneca

Approved

2 2

Plavix

Sanofi

Approved

1 3

Neoral

Alka-Seltzer

3 5

Adrenaline

SSamson Clinical Operations Pty Ltd

Approved

3 6

Kengreal

Chiesi Farmaceutici S.p.A.

Approved

1 7

Ativan

BBausch Health Americas, Inc.

Approved

1 8

Effient

CCosette Pharmaceuticals, Inc.

Approved

1 9

MS Contin

HHikma Pharmaceuticals LLC

Approved

—10

Ketalar

AAultman Health Foundation

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cardiac Arrest1 trial

Plasma Neutrophil Gelatinase-associated Lipocalin (NGAL) as Early Biomarker for Renal Dysfunction and Good Neurologic Outcome in Out of Hospital Cardiac Arrest Patients

Unknown status·YYonsei University··NCT01987466·73 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Serum NGAL level. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Serum NGAL level compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Serum NGAL level. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yonsei University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: YYonsei University

Serum NGAL level

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cardiac Arrest1 trial

References

Drug Info

Quick Facts

Related News